MedTrace Logo

Muscle Weakness Duration After Single Botulinum Toxin Injection in Masseter

NCT05309564 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-05-03

No results posted yet for this study

Summary

This study aimed to evaluate the duration of a reduced maximal voluntary bite force after a botulinum toxin intervention. Methods: In an intervention group, 25 units of Xeomin® (Merz Pharma GmbH \& Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A were injected into the masseter muscles bilaterally (to a total of 50 units).

Conditions

  • Bite Force
  • Botulinum Toxins, Type A

Interventions

DRUG

Botulinum toxin type A

Single intervention

Sponsors & Collaborators

  • Umeå University

    collaborator OTHER

  • Mahidol University

    collaborator OTHER

  • Region Västerbotten

    lead OTHER_GOV

Principal Investigators

  • 2020-03517 Pettersson, PhD · Umeå University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2022-01-10
Completion
2022-03-14

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05309564 on ClinicalTrials.gov